Downregulation of p53 promotes in vitro perineural invasive activity of human salivary adenoid cystic carcinoma cells through epithelial-mesenchymal transition-like changes

Yang,Xiangming; Jing,Da; Liu,Lijun; Shen,Zhiyuan; Ju,Jun; Ma,Chao; Sun,Moyi

doi:10.3892/or.2015.3750

Downregulation of p53 promotes in vitro perineural invasive activity of human salivary adenoid cystic carcinoma cells through epithelial-mesenchymal transition-like changes

Authors:
- Xiangming Yang
- Da Jing
- Lijun Liu
- Zhiyuan Shen
- Jun Ju
- Chao Ma
- Moyi Sun
View Affiliations

Affiliations: State Key Laboratory of Military Stomatology, Department of Oral and Maxillofacial Surgery, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China, Department of Biomedical Engineering, Fourth Military Medical University, Xi'an, Shaanxi, P.R. China
Published online on: January 26, 2015 https://doi.org/10.3892/or.2015.3750
Pages: 1650-1656

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Salivary adenoid cystic carcinoma (SACC) is a malignant tumor that is characterized by perineural invasion (PNI). p53 is an essential tumor-suppressor gene and p53 mutations play a critical role in tumor occurrence and progression (e.g., pancreatic, prostate and head and neck cancer). However, the regulatory role of the p53 gene in SACC and the PNI process remains unknown. In the present study, we employed RNA interference technique to downregulate p53 gene expression in SACC-83 cells to explore the role of p53 in the PNI process. Our results showed that the downregulation of the p53 gene induced significant ‘epithelial-mesenchymal transition (EMT)-like changes’ in SACC-83 cells, including decreased expression levels of epithelial markers (E-cadherin, EMA and CK5) and increased expression levels of mesenchymal markers (vimentin, N-cadherin and C-cadherin). The downregulation of p53 also caused a lower apoptotic index of Annexin V-FITC/PI and a lower number of SACC-83 cells in the second G0/G1 phase of the cell cycle. Furthermore, the downregulation of the p53 gene resulted in a significant increase in PNI activity in the SACC-83 cells. Thus, our findings revealed that downregulation of p53 promoted in vitro PNI activity through ‘EMT-like changes’ in SACC-83 cells. The present study suggests the essential regulatory role of p53 in the PNI activity of SACC cells, and implies that p53 may be a new target gene for the clinical treatment of SACC.

View Figures

View References

1	Khan AJ, DiGiovanna MP, Ross DA, Sasaki CT, Carter D, Son YH and Haffty BG: Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer. 96:149–158. 2001. View Article : Google Scholar : PubMed/NCBI
2	Chummun S, McLean NR, Kelly CG, Dawes PJ, Meikle D, Fellows S and Soames JV: Adenoid cystic carcinoma of the head and neck. Br J Plast Surg. 54:476–480. 2001. View Article : Google Scholar : PubMed/NCBI
3	Wiseman SM, Popat SR, Rigual NR, Hicks WL Jr, Orner JB, Wein RO, McGary CT and Loree TR: Adenoid cystic carcinoma of the paranasal sinuses or nasal cavity: a 40-year review of 35 cases. Ear Nose Throat J. 81:510–517. 2002.PubMed/NCBI
4	Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A and Siu LL: Imatinib mesylate in patients with adenoid cystic carcinoma of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol. 23:585–590. 2005. View Article : Google Scholar : PubMed/NCBI
5	Fordice J, Kershaw C, El-Naggar A and Goepfert H: Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolayrngol Head Neck Surg. 125:149–152. 1999. View Article : Google Scholar
6	Batsakis JG: Nerves and neurotropic carcinomas. Ann Otol Rhinol Laryngol. 94:426–427. 1985.PubMed/NCBI
7	Hassan MO and Maksem J: The prostatic perineural space and its relation to tumor spread: an ultrastructural study. Am J Surg Pathol. 4:143–148. 1980. View Article : Google Scholar : PubMed/NCBI
8	Rodin AE, Larson DL and Roberts DK: Nature of the perineural space invaded by prostatic carcinoma. Cancer. 20:1772–1779. 1967. View Article : Google Scholar : PubMed/NCBI
9	Ozaki H, Hiraoka T, Mizumoto R, Matsuno S, Matsumoto Y, Nakayama T, Tsunoda T, Suzuki T, Monden M, Saitoh Y, Yamauchi H and Ogata Y: The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection. Surg Today. 29:16–22. 1999. View Article : Google Scholar : PubMed/NCBI
10	Law WL and Chu KW: Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients. Ann Surg. 240:260–268. 2004. View Article : Google Scholar : PubMed/NCBI
11	Beard CJ, Chen MH, Cote K, Loffredo M, Renshaw AA, Hurwitz M and D’Amico AV: Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys. 58:19–24. 2004. View Article : Google Scholar
12	Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, Lui WY, Liu TJ and P’eng FK: Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg. 223:384–394. 1996. View Article : Google Scholar : PubMed/NCBI
13	Duraker N, Sişman S and Can G: The significance of perineural invasion as a prognostic factor in patients with gastric carcinoma. Surg Today. 33:95–100. 2003. View Article : Google Scholar : PubMed/NCBI
14	Savagner P: Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays. 23:912–923. 2001. View Article : Google Scholar : PubMed/NCBI
15	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
16	Jechlinger M, Grunert S, Tamir IH, Janda E, Lüdemann S, Waerner T, Seither P, Weith A, Beug H and Kraut N: Expression profiling of epithelial plasticity in tumor progression. Oncogene. 22:7155–7169. 2003. View Article : Google Scholar : PubMed/NCBI
17	Shi Y and Massagué J: Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 113:685–700. 2003. View Article : Google Scholar
18	Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 172:973–981. 2006. View Article : Google Scholar : PubMed/NCBI
19	Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM and Mills GB: Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69:4116–4124. 2009. View Article : Google Scholar : PubMed/NCBI
20	Tarin D, Thompson EW and Newgreen DF: The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 65:5996–6001. 2005. View Article : Google Scholar : PubMed/NCBI
21	Klymkowsky MW and Savagner P: Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe. Am J Pathol. 174:1588–1593. 2009. View Article : Google Scholar : PubMed/NCBI
22	Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855–4878. 1994.PubMed/NCBI
23	Brosh R and Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 9:701–713. 2009.PubMed/NCBI
24	Chen W, Zhang HL, Shao XJ, Jiang YG, Zhao XG, Gao X, Li JH, Liu BL and Sun MY: Gene expression profile of salivary adenoid cystic carcinoma associated with perinerual invasion. Tohoku J Exp Med. 212:319–334. 2007. View Article : Google Scholar : PubMed/NCBI
25	Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH and Hung MC: p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 13:317–323. 2011. View Article : Google Scholar : PubMed/NCBI
26	Tuschl T: Expanding small RNA interference. Nat Biotechnol. 20:446–448. 2002. View Article : Google Scholar : PubMed/NCBI
27	Dong L, Ge XY, Wang YX, Yang LQ, Li SL, Yu GY, Gao Y and Fu J: Transforming growth factor-β and epithelial-mesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma. Oral Oncol. 49:1051–1058. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zou W, Yang H, Hou X, Zhang W, Chen B and Xin X: Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increase chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett. 248:211–218. 2007. View Article : Google Scholar
29	Chen W, Zhang HL, Jiang YG, Li JH, Liu BL and Sun MY: Inhibition of CD146 gene expression via RNA interference reduces in vitro perineural invasion on ACC-M cells. J Oral Pathol Med. 38:198–205. 2009. View Article : Google Scholar : PubMed/NCBI
30	Wang L, Sun M, Jiang Y, Yang L, Lei D, Lu C, Zhao Y, Zhang P, Yang Y and Li J: Nerve growth factor and tyrosine kinase A in human salivary adenoid cystic carcinoma: expression patterns and effects on in vitro invasive behavior. J Oral Maxillofac Surg. 64:636–641. 2006. View Article : Google Scholar : PubMed/NCBI
31	Giono LE and Manfredi JJ: The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol. 209:13–20. 2006. View Article : Google Scholar : PubMed/NCBI
32	Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E and Peter ME: CD95 promotes tumour growth. Nature. 465:492–496. 2010. View Article : Google Scholar : PubMed/NCBI
33	Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O and Oren M: Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA. 86:8763–8767. 1989. View Article : Google Scholar : PubMed/NCBI
34	Baker SJ, Markowitz S, Fearon ER, Willson JK and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249:912–915. 1990. View Article : Google Scholar : PubMed/NCBI
35	Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, et al: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 10:5772–5781. 1990.PubMed/NCBI
36	Michalovitz D, Halevy O and Oren M: Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:671–680. 1990. View Article : Google Scholar : PubMed/NCBI
37	Martinez J, Georgoff I, Martinez J and Levine AJ: Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 5:151–159. 1991. View Article : Google Scholar : PubMed/NCBI
38	Zhang WW, Fang X, Mazur W, French BA, Georges RN and Roth JA: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1:5–13. 1994.PubMed/NCBI
39	Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T and Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 2:985–991. 1996. View Article : Google Scholar : PubMed/NCBI
40	Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S, Nabeya Y, Shuto K, Hayashi H, Tanizawa T, Nakatani Y, Nakasa H, Kitada M and Ochiai T: Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci. 97:554–561. 2006. View Article : Google Scholar : PubMed/NCBI
41	Brown CJ, Lain S, Verma CS, Fersht AR and Lane DP: Awakening guardian angels: drugging the P53 pathway. Nat Rev Cancer. 9:862–873. 2009. View Article : Google Scholar : PubMed/NCBI